拉莫三嗪,临床注释-2,变异和临床注释数据

拉莫三嗪

临床注释ID

1447676595

药物名称(英)

lamotrigine

变异单倍型

HLA-B*15:02:01

基因

HLA-B

证据级别

1A

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Toxicity

表现型类别

毒性

分数

107.5

PMID计数

9

计数的证据

11

表现型

表皮坏死松解症，毒性；癫痫；严重皮肤不良反应；Stevens-Johnson 综合征

表现型(英)

Epidermal Necrolysis, Toxic;Epilepsy;severe cutaneous adverse reactions;Stevens-Johnson Syndrome

最新日期

2022/3/1 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1447676595

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
699	*15:02:01	Patients with one or two copies of the HLA-B15:02:01 allele may have an increased risk for severe cutaneous adverse reactions when receiving lamotrigine as compared to patients with no HLA-B15:02:01 alleles or negative for the HLA-B*15:02:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of lamotrigine-induced adverse reactions.

临床证据

id	证据的ID	总结
692	1451780623	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine or lamotrigine.
691	1449169849	HLA-B *15:02:01 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.
690	1447676580	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.
689	1446902388	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine or valproic acid in people with Epilepsy.
688	1184988720	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.
687	1184466819	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with lamotrigine in people with Epilepsy.
686	1184466675	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with lamotrigine.
685	1183680901	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.
684	1183680871	HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.
683	981859078	HLA-B *15:02:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine in Epilepsy.
682	PA166265341	Annotation of DPWG Guideline for lamotrigine and HLA-B

临床病史

id	类型	评论
952	Note	Second curator check
951	Update	added DPWG guideline annotation, change in LOE
950	Update	CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.
949	Update	Updated OMB race to appropriate biogeographical group
948	Update	Added PMID 29238301
947	Create

最新招商产品更多>>